Fera acquires investigational new drug for treatment of fungal otitis externa

Fera Pharmaceuticals announces the acquisition of an investigational new drug to treat fungal otitis externa (FOE).

“This acquisition fulfills a key strategic imperative for Fera—product development and commercialization in specialty and underserved therapeutic categories”

In a Phase 2 pilot study, Itraconazole topical suspension was shown to be effective in the treatment of FOE with no adverse events reported. In addition, the drug has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA).

"This acquisition fulfills a key strategic imperative for Fera—product development and commercialization in specialty and underserved therapeutic categories" says Frank J. DellaFera, President of Fera.

The company is working to complete clinical development required to obtain FDA approval.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Urine RNA analysis shows promise for detecting genitourinary diseases